on behalf of Cours S€¦ · Pr. Axel Kahn (Ligue contre le Cancer) 03:00–03:30 PM: Future of...

on behalf of Cours St Paul

Dear Friends,

We are pleased and honored to report that the Third Edition of IFODS will be held in Paris from 20-22 October 2020. The Second Edition was a tremendous success, with over 600 participants in attendance. The quality talks and sessions have received such positive feedback across the board that we have decided to go ahead with our plans to create a major national oncology conference, in close collaboration with national oncology societies and leading international experts.

Meanwhile, we must continue to promote this conference to grow attendance year on year and to provide sustained excellence in oncology training. This is why we are moving the event to a more central and ac-cessible location in Paris. This venue is even more conducive to dialogue and communication, everything being on the same floor, whether it be the central forum where partners and participants can interact, the meeting rooms all around, or the auditorium for plenary sessions.

We are looking forward to welcoming you at the Rive Montparnasse business center, which is very close to Montparnasse train station.

As in previous editions, the French Cancer Society (SFC) is working alongside IFODS to organize a special opening session on the Future of Oncology, with contributions from scientists and young oncologists. Institution like EACR is also expected to provide renewed support.

IFODS seeks to promote the efforts of all who fight against cancer, by sharing the best and latest develop-ments in oncology as well as best practice guidelines. In line with this objective, IFODS is delighted to wel-come patients and patient groups to its Science Committee meetings and to a number of sessions. The conference will provide these honored guests with opportunities to learn about therapeutic approaches and to confer with healthcare providers.

France is a key player within the global field of oncology and, as such, deserves a world-leading confe-rence on a par with its excellent level of care.

Please join us in Paris from 20-22 October 2020, for the Third Edition of IFODS. As always, pride of place will go to training, dialogue, sharing and excellence in science, in a warm and friendly environment.

Thank you in advance for your support and participation. We hope to see you there! With kind regards, Jean-Philippe SPANOPresident of the IFODS Science Committee

Conférence Multidisciplinaire d’oncologie / Multidisciplinary Oncology Conference / Consensus and Guidelines for a better practiceSCIENTIFIC SYMPOSIUM ON PROGRAM

Scientific Symposia are sessions during which some of the world best experts will, upon invitation, address different issues related to a specific topic. Each scientific symposium will end with a round

table discussion and Q & A with the audience.

iTHE FUTURE OF ONCOLOGY (Basic Science) LA SEINE (PLENARY) • 02:30-04:30 PMUnder the aegis of SFC, EACR and AACR President: Manuel RodriguesChairpersons: Jacques-Olivier Bay, Jean-Pierre Armand & Marie Dutreix02:30–03:00 PM: Future of oncology care / Pr. Axel Kahn (Ligue contre le Cancer)03:00–03:30 PM: Future of oncology research / Pr. Hugues de Thé (EACR)03:30–04:00 PM: Artificial intelligence in oncology / Pr. Jean-Philippe Vert (Google Brain)04.00–04.30 PM: Financial Issues / Pr. Isabelle Durand Zaleski (Henri Mondor Hospital)

• 04:30-05:00 PM: pause / visite sur les stands / break

iAWARDS CEREMONY LA SEINE (PLENARY) • 05:00-06:00 PM• THESIS on behalf of AERIO, SFC & SFRJO

• CLAUDE JACQUILLAT on behalf of SFCHonorary Presidents: Edith Perez & Sandra Swain

iRENCONTRE MÉDECINS - PHARMACIENS : LE PARCOURS PATIENT EN 2020 : UNE APPROCHE MULTIDISCIPLINAIRE AU SEIN D’UN RÉSEAU VILLE – HÔPITAL MISSISSIPI • 02:30-04:30 PMPresidents: Georges GarnierChairpersons : Anne Charasse, Alain Astier, Bernard DO, Fanny Charbonnier Beaupel, Agnès Bellanger, Patrick Tilleul, Gérard Milano

02:30–03:00 PM: Le parcours de la biopsie liquide. Gérard Milano

04:30-05:00 PM: pause / visite sur les stands / break

oPOSTERS SESSION

iSESSION INFIRMIÈRESRECHERCHES EN SOINS, DE L’IDÉE À LA CLINIQUE INFIRMIÈRE ST LAURENT • 02:30-05:00 PMUnder the aegis of AFIC Présidente: Pascale DielensegerModérateurs: Pascale Dielenseger, Pierre Perroche- Recherche infirmière : quelle ossature de protocole ? Pascale Dielenseger, cadre de santé, IGR, VILLEJUIF

- Les effets de la méthode de la consultation par une infirmière clinicienne basée sur l’association de la théorie de Peplau (1952) et les méthodes psychocorporelles sur l’anxiété préopératoire des patients. Résultats et perspectives de recherche Marie-Paule Kolmayer, infirmière clinicienne La CNCPR : Commission Nationale des Coordonnateurs Paramédicaux de la Recherche, Marie-Adèle Ribeiro-Marthoud, Infirmière Cadre supérieures de Santé, Direction des Soins CHU Dijon-Bourgogne Membre de la CNCPR

- Suivi renforcé des patients sous thérapies anticancéreuses orales : mise en œuvre d'un programme de recherche paramédicale financé dans le cadre d'un PHRIP" Pierre Perroche, cadre de santé, CGFL, DIJON

3

TUESDAY 20th OCTOBER

02:00-02:30 PM iPLENARY ROOM

OPENING SESSION : Jean-Philippe SPANO

* to

be

con

firm

ed


WEDNESDAY 21st OCTOBER


4 FITI : From IFODS TO IFODS

iCONSENSUS AND GUIDELINES FOR BREAST CANCER (1) INNOVATION: ACCELERATE OR SLOW DOWN LA SEINE (PLENARY) • 09:00-12:30 AMUnder the aegis of St PaulPresidents: Marc Spielmann, Joseph Gligorov

PART I: ACCELERATE AND SLOW DOWN9:00–10:00 AM: Endocrine receptor positive breast cancers: are we moving to the end of the endocrine treatment alone?

9:00–09:20 AM: CDK4/6 inhibitors in ER positive MBC: Who do not benefit? Véronique Dieras

9:20–09:40 AM: PIK3CA inhibitors in PIK3CAmut ER positive MBC: Who not to test? Suzette Delaloge

9:40–10:00 AM: Optimizing endocrine treatment in EBC: What have we learn from TailorX and MINDACT trials? Johanna Wassermann

10:00 – 10:30 AM: pause / visite sur les stands / break

10:30–11:30 AM: HER2 positive breast cancers: is it time to redefine the disease and the treatment strategies? With the support of ROCHE

10:30–10:50 AM: Is the neaodjuvant strategy in HER2 positive breast cancers the optimal one? Jean-Yves Pierga

10:50–11:10 AM: Clinical interest of redefining HER2 positive disease? Frédérique Penault-Llorca

11:10–11:30 AM: New strategies in HER2 positive MBC? Sandra Swain

h11:30AM-12.30 PM • HIGHLIGHTS FITI SESSION ON BREAST CANCER (International Meetings Update)

With the support of NOVARTIS

h12:30-13:30 PM: SYMPOSIUMWith the support of PFIZER

oPOSTERS SESSION

h13:30 PM-14:00 PM

LUNCH COCKTAIL

iLA LEÇON DES IFODS LA SEINE (PLENARY) • 02:00-02:30 PMChairpersons: Edith Perez & Frédérique Penault-Llorca Speaker: Jérôme GalonPredictive factors in Immunotherapy : a signature or a Score ?

iCONSENSUS AND GUIDELINES FOR BREAST CANCER (2) INNOVATION: ACCELERATE OR SLOW DOWN LA SEINE (PLENARY) • 02:30-03:30 PMUnder the aegis of St Paul

02:30–03:30 PM: Triple negative breast cancers: what's new in neo-adjuvant? With the support of MSD

02:30–02:50 PM: Immune checkpoint therapies in triple negative breast cancers: a new standard? Edith Perez

02:50–03:10 PM: Systemic treatment for early breast cancers: any impacting news? (TBD)

03:10–03:30 PM: Towards more neoadjuvant chemotherapy ? How should the surgeon fit ? Catherine Uzan

iTHE NEWS OF 2020 IN CARCINOLOGICAL GYNECOLOGY (SGO, ASCO, ESMO) LA SEINE (PLENARY) • 03:30-04:30 PMUnder the aegis of SFCO & GINECO GROUP Presidents: Jean-Marc Classe & Isabelle Ray-Coquard

Chaipersons: Jérôme Alexandre and Jean-Marc Classe • Endometrial cancer: Renaud SABATIER• Ovarian cancer: (TBD)• Cervical cancer: Jérôme MARTIN-BABAU


5


* Late Breaking Abstract

GÉNOMIC SEQUENCING FOR ALL PATIENTS ? LA SEINE (PLENARY) • 04:30-05:30 PMUnder the aegis of St Paul & SFMPPWith the support of GSKPresidents: Pascal Pujol, Joseph Gligorov & Frédérique Penault-Llorca

04:30–04:50 PM: cancer genomics at Germline level: what's new in the era of multigene panel? Thibault de La Motte Rouge (TBC)

04:50–05:10 PM: Are we getting closed to extend circulating tumoral DNA use in clinical practice: Interest for récurrence detection in ovarian cancer? Véronique Haddad

05:10–5:30 PM: Clinical guidelines for BRCA1/2 genetic testing in the era of PARP inhibitors : an overview and the recommendations of the SFMPP. Frédérique Penault-Llorca


iCONSENSUS AND GUIDELINES FOR GI TUMORS MISSISSIPI • 09:00-12:30 AMUnder the aegis of Prodige Group, UNICANCER GI, GERCOR & FFCDChairperson: Christophe Louvet

9:00–9:20 AM: Adjuvant treatment for GI cancers (except for biliary tree): 2019 update. Eric Assenat9:20–9:40 AM: Adjuvant treatment for biliary tree cancers. Julien Edeline

9:40–10:00 AM: IDEA lessons beyond treatment duration. Thierry André

10:00–10:20 AM: Follow-up after colon cancer surgery. Côme Lepage

Discussion (10 minutes)

10:30 – 11:00 AM: pause / visite sur les stands / break

11:00–11:30 AM: Beyond Folfirinox and Gem Abraxane, what else in advanced pancreatic cancer treatment ?(TBD)

11:30–11:50 AM: Oncogenetic and GI cancers. Rosine Guimbaud

11:50–12:10 AM: Metastatic colorectal cancer: 3rd line and after. Emmanuelle Samalin

Discussion (10 minutes)

12:20–12:30 AMConclusion. Christophe Louvet h12:30 AM-02:00 PM

MISSISSIPI • LUNCH/DEBATE PAN TUMORSWith the support of Pierre Fabre iCONSENSUS AND GUIDELINES FOR DERMATOLOGY MISSISSIPI • 02:30-04:00 PM Presidents: Celeste Lebbe Chairpersons: Barouyr Baroudjian, Donia Lassoued & Stéphane Barete

2:30–2:45 PM: Adjuvant and neoadjuvant treatment of melanoma. Barouyr Baroudjian

2:45–3:00 PM: New therapeutic combinations: news from the AACR. Cristina Libenciuc

3:00–3:15 PM: How to monitor our long-term responders? Lise Boussemart

3:15–3:30 PM: What are the serious toxicities of immunotherapy? Caroline Dutriaux

3:30–3:45 PM: Management of brain and meningeal metastases. Jérêmy LupuDiscussion (15 minutes)

iDUETS SESSION BISPECIFIC ANTIBODIES AND CAR TCELLS: ALONE OR IN COMBINATION? MISSISSIPI • 04:00-05:00 PM Presidents: Edith Perez & Fanny Charbonnier Speakers: Paul Gougis & Nicolas PoirierCART-cells in the field of solid tumors. Paul Gougis Bispecific Anti-PD1 to Tackle Immune Resistance Mecanism. Nicolas Poirier

4

* to

be

con

firm

ed

6



iCONSENSUS AND GUIDELINES FOR UROLOGY TRI-MODAL TREATMENTS: FOR OR AGAINST? ST LAURENT • 09:00-12:30 AM Under the aegis of AFU Presidents: Thierry Lebret, David Azria, Ronan Flippot & Arnaud Méjean

3 CLINICAL CASES: FOR / AGAINST1. Kidney: 62-year-old man bilateral kidney tumor with vascular thrombus on the right and a single synchronous meta on the lungPlace of surgery (total + partial + metastasectomy) and discussion of adjuvant tKiIdir OuzaidTKi treatment without surgery. Yann Alexandre Vano

- Discussion and conclusion: Ronan Flippot

2. Urothelium: 62-year-old T2G3 bladder man, resection deemed complete and Tep Scan negative.Why offer a complete resection with radio-chemotherapy ?David AzriaWhy not offer this solution ?Alexandra Masson Lecomte- Discussion and conclusion: Thierry Lebret

3. Prostate: 62 year old man Gleason 8 (4 + 4), clinical T2 doubt on T3 MRI and PSA at 16ng / ml.Place of primary surgery associated with radio-hormone therapy. François Rozet

Why stay at Bolla without first surgery. (TBD)- Discussion and conclusion: Arnaud Méjean

11:15-12:30 AM: SYMPOSIUM With the support of IPSEN

oPOSTERS SESSION

10:30-11:00 AM: pause / visite sur les stands / break

h12:30-2:00 PM ST LAURENT •

iCONSENSUS AND GUIDELINES FOR RADIOTHERAPY ST LAURENT • 02:30-05:00 PM Under the aegis of SFROPresident: Philippe Giraud

Chairpersons: David Azria, Florence Huguet, Philippe Maingon, Françoise Mornex

Proton Therapy - Validated Indications and Prospects in France. Jérôme Doyen

New dose constraints in radiotherapy of brain tumors, based on the cognitive impairment and morphological changes after radiation therapy.Julian Jacob

State of the art of radiobiology and its projects in France in 2020. David Azria

Recommendations for radiotherapy of a patient with a pacemaker / defibrillator. Marc Laurans

Computer system safety in Radiation Oncology.Charlotte Drapeau


FITI : From IFODS TO IFODS

7


* sous réserve de confirmation des participants* Late Breaking Abstract

THURSDAY 22nd OCTOBERiCONSENSUS AND GUIDELINES FOR LUNG CANCER (1) LA SEINE (PLENARY) • 09:00-12:30 AMUnder the auspices of our respective groups: IFCT, Oncology Group/SPLF Présidents: Marie Wislez, Fabrice Barlesi Chairperson(s): Françoise Mornex, Frances Shepherd, Pierre-Jean Souquet

09:00-09:30 AM: what are and what would be the biomarkers to look for to predict the efficacy of immunotherapy? Eric Tartour

09:30-10:00 AM: How and why genotype naive advanced NSCLC pts? Federico Capuzzo

10:00-10:30 AM: Which first-line treatment for NSCLC patients without addiction? Maurice Pérol

10:30-11:00 AM: pause / visite sur les stands / break

11:00-11:30 AM: How to manage EGFR and ALK resistances in 2020? Enriqueta Felip

11:30-12:00 AM: Initiatives to improve efficacy, accessibility and affordability of lung cancer care in the future? The IASLC pathway. Giorgio Scagliotti

Discussion

oPOSTERS SESSION

h12:30PM-13.30 PM

LA SEINE (PLENARY) • IMMUNOTHERAPYHIGHLIGHTS FITI* SESSION (International Meetings Update)

With the support of MSD

h13:30 PM-14:00 PM LUNCH COCKTAIL iATELIER SPORT & CANCER LA SEINE (PLENARY) • 02:00-04:30 PMUnder the aegis of CAMIPrésidents : Thierry Bouillet & Jean-Marc Descotes« Présentation de l’Enquête co-menée avec le Laboratoire PFIZER sur les leviers et freins à la pratique de l’activité physique adaptée chez des patients atteints de cancer métastatique »

13h30 : Accueil

14h00 : Introduction. Thierry Bouillet (Co-fondateur et Président de la CAMI Sport & Cancer)

14h15 : Présentation de l'enquête et des résultats. (TBD)

15h15 : Table Ronde – Quels enseignements tirés de cette enquête? (TBD)

16h : Intervention de deux grands témoins. (TBD)

16h20 : ConclusionJean-Marc Descotes (Co-fondateur et Directeur Général de la CAMI Sport & Cancer)

h05:00-05:30 PM

oPOSTERS AWARD

i LA PAROLE EST AUX PATIENTS ST LAURENT • 09:00-10:30 AM Sous l’égide des associations de patients, Europa Donna, Life is Rose, Rose MagazineUniversité des patients Sorbonne Université, Nathalie Savariaud, Jean-Jacques Zambrowski, Maryline Baranes, Natacha Espié, Gary Rodin, Françoise Debiais, Edith Perez, Joseph Gligorov, Laure Accolas, Céline Dupré et Céline Lis-Raoux

09:00-10:30 : Les problèmes sociaux et de logement rencontrés au moment et après la maladie

i « INNOVATION RELATIONNELLE » Bénéfices-Risques dans la relation Médecin-Patient et dans la mise en place des traitements : le cas de la simulation d’annonce en Oncologie

ST LAURENT • 11:00-12:00 AM

i LA SOFOM AUX IFODS ST LAURENT • 12:00-12:30 AM

h12:30PM-13:00 PM • FLASH MEET THE PROFESSORWith the support of LEO PHARMA

8

THURSDAY 22nd OCTOBER


* FITI : From IFODS TO IFODS

iMANAGEMENT OF CARDIOVASCULAR COMPLICATIONS IN CANCER PATIENTS ST LAURENT • 02:00-03:30 PMChairperson(s): Joe-Elie Salem (Paris), Francis Cajfinger (Paris)1. Myocarditis Induced by Immune-Checkpoint Inhibitors: Clinical features, management, andoutcomes. Stéphane Ederhy (Paris)2. International Guidelines for the treatment of Venous thromboembolism in Cancer Patients. Corinne Frere (Paris)3. Clinical features and Management of Atrial Fibrillation in Cancer Patients. Joaquim Alexandre (Caen)

i BIOTECH IN ONCOLOGY ST LAURENT • 03:30-05:00 PM Under the aegis of Gustave Roussy Transfert, Cancer Campus and Angels Santé Startup Showcase Session (open to academic projects and start-ups): presentation pitch of your project (7 min) in front of the IFODS audience in the presence of experts, investors and potential partners

Networking session with investors, pharmas, oncologists, researchers

iHOW TO MANAGE BREAST CANCER ACCORDING TO THE MEANS: « THE MINIMAL REQUIREMENTS AND STANDARDS » AROME CONCEPT MISSISSIPI • 09 :00-11 :00 AM Sous l’égide de AROMEChairperson(s): Joseph Gligorov, Yazid Belkacemi1. Introduction. Joseph Gligorov (AROME President) 2. Minimal requirements for diagnosis:Is MRI a minimal requirement for breast cancer imaging.Thu Ha DaoThe Pathology report: from minimal to standart. Nina Radosevic3. Loco-regional therapy: Is SLNB the minimal for all BC. Marie Pierre Chauvet Is hypofractionation breast RT the standart For all patients with BC in emergeant countries. Yazid Belkacemi 4. Access for innovation in systemic therapy :

A report from the AROME Budva Consensus. Joseph Gligorov

n Discussion and Closing remarks

iCONSENSUS AND GUIDELINES FOR SARCOMA MISSISSIPI • 11:00-12:30 AMUnder the aegis of GSF-GETO & NET-SARCPresidents: Jean-Yves Blay & Axel Le CesneChairperson: Aurore Vozy, Sixtine De Percin

What’s new in 2020 ?• Surgery• Radiotherapy• Chemotherapy• Targeted Immunotherapy• Central role of CPR, « A multidisciplinary approach »

h12:30PM-13:30 PM

MISSISSIPI • SYMPOSIUM " SMALL CELL LUNG CANCER : ADVANCES AND CHALLENGES"With the Support of AstraZeneca Chairperson(s): Marie Wislez, Fabrice Barlesi, Virginie Westeel

Towards a new characterization of small cell lung cancers? Immunobiological aspects and new molecular classification. Audrey LupoIs there a new standard in small cell lung cancer therapy ? Frances ShepherdProspects and challenges: towards personalized treatment ? Gerard Zalcman

iCONSENSUS AND GUIDELINES FOR LUNG CANCER (2) MISSISSIPI • 02:00-03:30 PMUnder the auspices of our respective groups: IFCT, Oncology Group/SPLF Présidents: Marie Wislez, Fabrice Barlesi Chairperson(s): Virginie Westeel, Céline Mascaux

02:00-02:30 PM: Smoking cessation: benefits and risks of vap. Anne-Marie Ruppert

02:30-03:00 PM: How to best organize the multimodality management of lung cancer patients? Laurent Greillier

03:00-03:30 PM: Is there a new hope for ECOG PS2+/comorbidities patients ? Sanjay Popat

8 9


iINTERACTIVE WEBCONFERENCE: MULTIDISCIPLINARY BOARD/BONE METS OF LUNG CANCER MISSISSIPI • 03:30-04:30 PMSous l’égide du groupe GEMO Presidents: Marie-Hélène Vieillard & Frédéric ClarençonChairperson(s): Laetitia Morardet, Matti Aapro


THURSDAY 22nd OCTOBER

- Abstracts have to be submitted electronically and in English- Abstracts received after the deadline (September 10th, 2020) will not be considered- Supply as much information as possible: the precise subject of study, methods used where appropriate, summary of results obtained, conclusion- As it is assumed that original work will be presented, no bibliographic references are necessary- Selected abstracts will be published in the abstract book exactly as you submitted it. Therefore, proofreading is essential, no modification will be possible after submission.- Your abstract should not contain accents or any other invalid character, which would not be part of the English alphabet.- Your abstract’s text should not exceed 3,000 characters (excluding spaces)- The main author (presenter) confirms that all authors are aware of and agree to the content of the abstract and support of the data presented. By submitting his abstract, the author allows the IFODS to publish and distribute or sell his abstract as part of the Abstract Book, which may be distributed on paper.- All selected abstracts will be published in the abstract book. Papers accepted for IPOSTER presentation will be displayed during poster sessions.- Acceptance or rejection of the paper by the Scientific Committee will be notified by email to the main author (presenter) by September 14th, 2020- Only persons whose registration is complete will be able to present their abstracts- IPOSTERS will be awarded or encouraged: a special jury will select the three best posters and their authors will receive IFODS Poster Award and a cheque of 500E each.

Registration (Allows to access all satellite meetings of the IFODS)

REGISTRATION FEES (in Euros)

1 Day Regular Registration Regular Registration

From Nov. 15th 19 to June. 15th 2020

p 200 e p Tuesday October 20th 2020 p Wednesday October 21st 2020 p Thursday October 22nd 2020

p 500 e

From June 16th 2020 and on site

p 250 e p Tuesday October 20th 2020 p Wednesday October 21st 2020 p Thursday October 22nd 2020

p 600 e

Student registration fees (Including breaks and 2 lunch) p 100 €(The participation of student is conditioned by the full coverage of their hospitality costs)

WAY OF REGISTRATIONOnline Registration: secure online registration and payment by credit card via the website www.ifods.comRegistration will be validated only with payment by credit card (Visa, Mastercard).Registration Form sent by Fax or Mail:you can download the registration form on the website and send it duly completed to the Organisation Committee.Registration will be validated only with payment attached or credit card information completed.Cancellation PolicyBefore July 10th, 2020: 50% cancellation feesFrom July 11th, 2020: no refund


International Medical Events (IME )19-21 rue Saint Denis - 92100 Boulogne-Billancourt - France - Email: [email protected] CommitteeContact : Valérie CAILLON : Tel : + 33 1 41 04 04 04 - Fax : +33 1 41 04 04 11 Email: [email protected] Information & AccommodationContact : Mathilde MANGIN : Tel : + 33 1 41 04 04 04 - Fax : +33 1 41 04 04 11Email: [email protected]

SUBMISSION GUIDELINES

AbstractsSubmission Deadline:

September 10th, 2020

ABST

RACT

10FITI : From IFODS TO IFODS

PCOMedical Department

[email protected]. : 00 33 (0)1 41 04 04 04 / Fax : 00 33 (0) 1 41 04 04 11

GareMontparnasse

Falguière

RIVE MONTPARNASSE

Edgar Quinet

M

M M

MGaitée

Rue

du d

épar

t

Boulevard du Montparnasse

Rue

de R

enne

s

Avenue du M

aine

Bouleva

rd de Va

ugirard

Rue

de l’A

rrivé

e

Rue Armand M

oisant

44 Boulevard de Vaugirard, Paris 15e

M

Lignes 4, 6, 12 et 13 (Montparnasse, Gaitée)

BUSLignes n°28, 58, 91, 92, 94, 95, 96, 88

BATEAUYachts de Paris

PARKINGParking PasteurInterparking

LOCALISATIONET ACCÈS

CONGRESS LOCATION RIVE MONTPARNASSE

11

EQU

ATO

UR

-IM

075

10

0360

RC

Par

is B

343

9036

3900

031

GLOBAL MEETINGS PROGRAM - TICKETS PURCHASINGThe Discount Agreement will be for travel between June 2nd through June 18th, 2020.

To benefit from these special offers, link up with http://globalmeetings.skyteam.com and quote the Identifier Code 36 189 AF Tickets purchased on the following Carriers are eligible for the SkyTeam Global Meetings programme:

Aeroflot, Aerolíneas Argentinas, Aeroméxico, Air Europa, Air France, Alitalia, China Airlines, China Eastern, China Southern, Czech Airlines, Delta Air Lines, Kenya Airways, KLM Royal Dutch Airlines, Korean Air, Middle East Airlines, Saudia, TAROM,

Vietnam Airlines and Xiamen Air.

To book your travel now, visit www.skyteam.com/GlobalMeetings and enter your Event ID, 36 189 AF

AIR FARE DISCOUNT - Event ID : 36 189 AFSkyTeam Global Meetings Agreement - This Agreement is entered into by and among member airlines of the SkyTeam Alliance and EQUATOUR. The airlines of SKYTEAM, Official Alliance Network for the IFODS 2020, offer attractive airfares for participants.

SKYTEAM comprises 19 leading international airlines serving 1000 destinations in 187 countries with over 15 000 flights daily.

Whether you are the organiser or the participant, the Global Meetings Program allows you to benefit from the expertise of SkyTeam’s network covering over 1,000 destinations worldwide. Via the online portal, not only can participants obtain discounted travel, but fl ights and connections are made more convenient. Organisers can also take advantage of an online solution especially designed to meet their needs, including a productivity reward program. Additionally, we provide you with a communications kit and one point of contact to help manage your event. Visit our website www.skyteam.com/globalmeetings

Through this site you can also access the schedules of all SkyTeam partners to plan your flights on the airline of your choice.

on behalf of Cours S€¦ · Pr. Axel Kahn (Ligue contre le Cancer) 03:00–03:30 PM: Future of...

Documents

Transcript of on behalf of Cours S€¦ · Pr. Axel Kahn (Ligue contre le Cancer) 03:00–03:30 PM: Future of...